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Background: Dexmedetomidine can be used for the prevention of emergence agitation (EA) in children. However,
an inadequate dose of dexmedetomidine can induce prolonged sedation and cardiovascular complications. The
aim of this study was to evaluate the effective dose of dexmedetomidine for the prevention of EA after desflurane
anesthesia for patients undergoing a tonsillectomy or adenoidectomy.
Methods: We enrolled 21 unpremedicated children, between 2 and 12 years, undergoing either a tonsillectomy or
an adenoidectomy. General anesthesia was induced using sevoflurane and oxygen, and dexmedetomidine was
administered before surgery. Anesthesia was maintained using desflurane resulting in a BIS range of 40–60. In the
postanesthetic care unit (PACU), EA (agitation measured at level 4 or more at least once) was assessed on arrival in
the PACU,15 min later, and 30 min later. The dose of dexmedetomidine for consecutive patients was determined
by the response of the previous patient, using an increment or decrement of 0.1 μg/kg.
Results: The 50 % effective dose of dexmedetomidine for prevention of EA was 0.25 μg/kg (95 % confidence limits,
0.17–0.33 μg/kg), and the 95 % effective dose was 0.38 μg/kg (95 % confidence limits, 0.29–0.39 μg/kg).
Conclusions: For prevention of EA after desflurane anesthesia for 50 % and 95 % of children undergoing
tonsillectomies or adenoidectomies, 0.25 μg/kg or 0.38 μg/kg of dexmedetomidine is suggested. Further study is
needed to validate the suggested dose of dexmedetomidine to prevent the EA that was identified in the present
study.
Trial registration: Clinical Research Information Service KCT0000126.
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Emergence agitation (EA) is one of the most common
complications of sevoflurane and desflurane anesthesia
in children and requires proper management. The inci-
dence of EA varies in the literature from 2–80 %
depending on the anesthetic technique and scoring scale* Correspondence: jinoben@naver.com
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unless otherwise stated.[1–3]. There were many trials conducted to manage or
prevent EA in children. Dexmedetomidine, a selective α2
agonist, has recently been used with some success as a
treatment for the prevention of EA [4]. Various doses
(0.15–1.0 μg/kg) of dexmedetomidine have been re-
ported to prevent EA in children undergoing sevoflurane
anesthesia [5–10]. Due to respiratory irritation, desflur-
ane is a less popular volatile agent for children than
sevoflurane. Desflurane has been shown to induce a
shorter duration of EA than sevoflurane [11]. Switching
from sevoflurane to desflurane after the anestheticis is an Open Access article distributed under the terms of the Creative
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risk of airway irritation. However, there has been insuffi-
cient research on the appropriate dosage of dexmedeto-
midine to prevent EA in children undergoing desflurane
anesthesia. A sedative, dexmedetomidine, does not cause
respiratory depression, but it does have cardiovascular
effects, and therefore its use requires close monitoring,
especially in children [12]. However, there was no defin-
ite dose of dexmedetomidine recommended to prevent
EA while prolonged sedation and cardiovascular compli-
cations did not occur. The aim of this study was to iden-
tify the optimal dose of dexmedetomidine needed to
prevent EA in children after a tonsillectomy or adenoi-
dectomy under desflurane anesthesia without serious
complications.
Methods
The present study was conducted in accordance with the
Declaration of Helsinki (World Medical Association).
After obtaining institutional review board approval from
Seoul National University Hospital and written informed
consent from parents or guardians, patients eligible for in-
clusion in the study—those between 2 and 12 years of
age, classified as ASA status I or II, and scheduled for
either an adenoidectomy alone or both an adenoidect-
omy and tonsillectomy —were selected using Dixon’s
up-and-down sequential method rather than random se-
quence. Patients with cardiac disease, abnormal upper air-
way, reactive airway diseases such as asthma, allergies to
dexmedetomidine or a history of upper respiratory tract
infection in the preceding 4 weeks were excluded. Patients
receiving medications known to interact with dexmedeto-
midine such as lorazepam, diphenhydramine or furosem-
ide were also excluded.
Intravenous accesses were secured on all children on
the day before the surgery by experienced nurses. Pre-
medication was not administered. Upon arrival in the
operating room, the children were monitored with elec-
trocardiography (ECG), pulse oximetry (SpO2), capno-
graphy, and noninvasive arterial blood pressure (NIBP)
(Solar 8000, GE, Milwaukee, WI). In addition, the
bispectral index (BIS: Vista™, Aspect Medical Systems
Inc, Newton, MA) was checked. Anesthesia was induced
with 6 mg/kg of sodium pentothal and 0.02 mg/kg of
atropine sulfate. After loss of consciousness, children were
ventilated with 8 vol. % of sevoflurane in oxygen via a
pediatric circle system. They were fully relaxed with
0.6 mg/kg of rocuronium and intubated with an endo-
tracheal tube. Anesthesia was maintained using 6–8 vol. %
of desflurane in approximately 50 % oxygen in air with a
total inflow of 2 L/min. The concentration of desflurane
was adjusted to a BIS range of 40-60. Before the start of
surgery on the first patient, 0.5 μg/kg of dexmedetomidine
(Precedex inj™, 200 mcg/ml, Hospira Inc., Lake Forest, IL,USA) diluted in 10 ml of normal saline was slowly
injected for 10 min and both the blood pressure and
heart rate were checked at one minute intervals. Dex-
medetomidine was prepared and injected by an
anesthesiologist who did not participate in the assess-
ment of EA. All tonsillectomies were performed using
coblation to prevent postoperative complications in-
cluding pain [13–15]. A 3 ml dose of 0.25 % bupiva-
caine and an epinephrine mixture (ratio of 1:200 000)
were injected into the mucosa surrounding each tonsil-
lar fossa. At the end of surgery, the desflurane was
stopped and extubation was performed when the pa-
tients began breathing spontaneously and could open
their eyes on command. Recovery times from the cessa-
tion of desflurane to the point at which patients’ eyes
opened were recorded. The patients were transferred to
the postanesthetic care unit (PACU) when fully awake.
One parent was allowed to remain with the child. In
the PACU, the ECG, NIBP, SpO2, and the respiratory
rate were checked and recorded.
EA was evaluated using the agitation scale developed
by Cole et al. (Table 1), [16] and the worst EA score
observed during the previous period was recorded by a
single anesthesiologist blinded to the sequence of in-
clusion of patients and to the dose of dexmedetomi-
dine administered to each patient. Recordings were
made on arrival at PACU (T = 0), and 15 and 30 min
later (T = 15, T = 30, respectively). EA, defined as an
agitation score of 4 or 5 occurring at least once during
surgery, was treated with 0.1 μg/kg of nalbuphine.
The dosage of dexmedetomidine was determined by
Dixon’s up–and -down sequential method [17]. If a child
showed EA, the next one received a dose 0.1 μg/kg greater.
If no EA was observed, the next dose of dexmedetomidine
was decreased by 0.1 μg/kg. The pain score was measured
using the Wong-Baker face pain rating scale during the EA
evaluation [18]. Nalbuphine 0.1 μg/kg was used as a rescue
medicine for patients with EA or pain scores > 8. Dixon’s
method requires at least six failure-success pairs for statis-
tical analysis, therefore recruitment continued until six
crossover pairs had been observed. A 50 % and 95 %
effective dose of dexmedetomidine along with 95 %
confidence intervals (CIs) were calculated using the
isotonic regression method, [19] an adjusted response
probability was obtained through use of the pooled
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using the bootstrapping approach [20, 21].
Demographic and recovery profile data between chil-
dren with EA and those without EA were compared
using Fisher’s exact test and the Mann–Whitney U test.
Statistical analyses were performed using R − 2.15.2 for
Windows and SPSS 19.0 (SPSS Inc., Chicago, IL). Statis-
tical significance was defined as P < 0.05.
Results
Twenty one children were enrolled and completed this
study; it is worth noting that no children dropped out,
which allowed us to observe six crossover pairs (Fig. 1).
Fig. 2 shows the sequences of dexmedetomidine dosages
used. Neither bradycardia or hypotension occurred in
any of the children following the administration of dex-
medetomidine. Patient and operative characteristics were
delineated in Table 2 and children with and without EA
differed in demographic data or recovery profile only for
the duration of their time in the PACU. The end-tidal
desflurane concentration was recorded 15, 30 and
45 min after the administration of dexmedetomidine,
and there was no significant difference in the mean of
the end-tidal desflurane concentration between the chil-
dren with and without EA. (Table 2) Nine patientsFig. 1 CONSORT diagram showing the flow of participants in present studdeveloped EA in the PACU and were given nalbuphine
0.1 μg/kg, after which all had EA scores < 4. The 50 % ef-
fective dose of dexmedetomidine for the prevention of EA
was 0.25 μg/kg (95 % confidence limit, 0.17–0.33 μg/kg),
and the 95 % effective dose was 0.38 μg/kg (95 % confi-
dence limit, 0.29–0.39 μg/kg). Pain scores were mea-
sured during the EA evaluation. Patients with EA had
greater pain scores (median (IQR)) than those who felt
relaxed (T = 0: 6.0 (5.0–9.5) vs. 4.0 (2.0–7.5), T =15: 6.0
(4.0–6.0) vs. 0 (0–2.0), and T = 30: 4.0 (3.0–5.0) vs. 2.0
(0.5–2.0), respectively). Five patients had pain scores > 8
at least once, for which they were given nalbuphine
0.1 μg/kg. The duration of patients’ PACU stay was
significantly greater in those with EA than those with-
out. No respiratory depression, hypotension or desatur-
ation (<95 %) was observed in the PACU.
Discussion
Inhaled anesthetic agents with low blood-gas solubility
such as sevoflurane and desflurane have clinical advan-
tages in allowing rapid induction and emergence. Sevo-
flurane is widely used as an inhalation anesthetic in
children to avoid the airway irritation that desflurane
causes during the anesthetic induction period. Sevoflurane
anesthesia, however, is associated with a higher incidencey
Fig. 2 Assessment of success or failure for preventing emergence agitation (EA) in the postanesthetic care unit with dexmedetomidine by the use of
Dixon’s up-and-down method. Crossover pairs from success (black circle) to failure (white circle) in preventing emergence agitation
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anesthetics or propofol whereas [22–25] desflurane is also
associated with EA in children with a similar incidence
but shorter duration of EA [11, 26, 27]. Desflurane may
have the clinical advantage of reducing the duration of EA
in children, therefore, there was a need to evaluate the
optimal dose of dexmedetomidine to prevent EA in chil-
dren under desflurane anesthesia. In our study of children
undergoing either a tonsillectomy or adenoidectomy
under desflurane anesthesia, 0.25 μg/kg of dexmedetomi-
dine prevented EA in 50 % of children, and 0.38 μg/kg
prevented EA in 95 %.
For the prevention of EA in children, various doses of a
single bolus of dexmedetomidine (0.15–1.0 μg/kg) or
timings of the single bolus of dexmedetomidine (immedi-
ately after anesthesia induction or 5 min before the end ofTable 2 Comparisons between children without EA and those with
Patients
Male/female 3/9
Age (yr) 6.0 (3.0 –
Weight (kg) 25.5 (20.
Height (cm) 124.3 (11
Duration of operation (min) 36.0 (34.
Duration of anesthesia (min) 52.0 (47.
End-tidal desflurane concentration (%) 6.1 ± 0.9
Recovery time from anesthesia (min) 8.0 (7.0 –
PACU Stay (min) 32.0 (27.
EA, emergence agitation
Values are presented as number of patients, or the median (interquartile range)
Age is presented as the median (range)
*P < 0.01surgery) have been recommended [5, 7, 28]. Continuous
infusion also decreases the incidence and frequency of
EA in children with sevoflurane anesthesia [9, 29].
Although these previous studies focused on whether
dexmedetomidine reduces the incidence of EA in chil-
dren, there has been little research into what dosage of
dexmedetomidine induces prolonged sedation or car-
diovascular instability. The 50 % and 95 % effective
doses of dexmedetomidine for the prevention of EA
(0.25 μg/kg and 0.38 μg/kg, respectively) determined
using Dixon’s up–and-down sequential method in the
present study are relatively low when compared to
those reported in previous studies. These effective
doses can serve as appropriate guidelines for not only
preventing EA but also reducing the risk of complica-
tions related to dexmedetomidine overdose.EA
without EA (n = 12) Patients with EA (n = 9)
2/7
7.0) 5.0 (3.0 – 7.0)
3 – 30.5) 21.5 (15.4 – 24.9)
1.3 – 127.8) 120.0 (101.4 – 123.7)
2 – 40.0) 31.0 (28.0 – 38.5)
2 – 60.7) 50.0 (47.0 – 57.5)
6.3 ± 1.0
9.0) 8.0 (6.25 – 10.0)
0 – 34.0) 39.0 (34.0 – 42.5)*
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dine (0.4 μg/kg or 0.5 μg/kg) used in this study, we did
not observe complications of dexmedetomidine such as
bradycardia, hypotension or prolonged recovery time.
The reason may be that the doses of dexmedetomidine
used in the present study were not high enough to
induce these complications [30]. The timing of dexme-
detomidine administration may also have prevented
complications. A bolus of dexmedetomidine was given
immediately after anesthesia induction. Stimulus by tra-
cheal intubation and 0.02 mg/kg of atropine sulfate
given before anesthesia induction might also prevent
such hemodynamic changes. Considering the short half-
life (2 h) of dexmedetomidine, it can be metabolized
after being administered, thus preventing a prolonged
recovery time.
There are several agitation scales, such as the Pediatric
Anesthesia Emergence Delirium, which are used to evalu-
ate EA in children. The present study used an agitation
scale that was employed in previous studies reporting a
preventive effect of dexmedetomidine on EA in children
[7–9]. The dose of dexmedetomidine (0.5 mcg/kg) admin-
istered to the first child in our study was based on the
results of these previous studies. We hypothesized that
using the same scale to evaluate EA would be appropriate
for determining the effective dose of dexmedetomidine to
prevent it and for comparison to previous studies. How-
ever, a single EA scale was used to define it in the present
study. The evaluation of EA could have been more reliable
if an additional EA scale had been used in conjunction.
After all, caution should be exercised when applying the
results of the present study to patients while using differ-
ent scales and definitions of EA for the assessment of EA.
Postoperative pain was more severe in patients with
EA than in those without EA in the present study. This
is for two reasons: first, postoperative pain can be a
cause of EA, and secondly, the EA scale and Wong-Baker
face pain rating scale have several common features.
The EA evaluation should have been conducted when
children were in a pain-free state to rule out the effect
of postoperative pain. However, the aim of the study
was to determine the effective dose of dexmedetomi-
dine necessary to prevent EA in children undergoing
tonsillectomies or adenoidectomies, and several methods,
were performed to reduce postoperative pain, such as a
surgical technique which uses coblation and the mucosal
injection of local anesthetics surrounding the tonsillar
fossa. In addition, dexmedetomidine has been reported to
reduce postoperative opioid requirements after a tonsillec-
tomy and adenoidectomy [29]. As a result, despite the
absence of an analgesic administration before emergence,
the incidence of postoperative pain was lower in patients
the present study than in those who had received acet-
aminophen in previous studies [7].This study had certain limitations which make it diffi-
cult to draw comparisons to previous studies. First, EA
can be influenced by many factors (pain, hunger, post-
operative nausea and vomiting, and fear of strangers)
during the perioperative period. Furthermore, though
Dixon’s up-and-down sequential method was used, the
sample size of the present study was relatively small.
Further clinical research to validate the suggested dose
of dexmedetomidine to prevent EA should be performed
in the future. Second, the ages of the children in the
present study were intended to range from 2 to 12 years
old. However, in practice, the age range of the children
enrolled was 3–7 years old, and the influence of age on
the dose of dexmedetomidine may be not significant.
Finally, children in the present study did not receive any
premedication so as to avoid additional variability of
responses. The effective dose of dexmedetomidine to
prevent EA may have been different if children had
received premedication to relieve their anxiety before
the anesthetic induction.
Conclusions
In conclusion, to prevent EA in 50 % or 95 % of children
undergoing tonsillectomies or adenoidectomies follow-
ing desflurane anesthesia, a single bolus of 0.25 or
0.38 μg/kg of dexmedetomidine is suggested. Further
clinical trials need to be conducted in order to validate
the suggested dose of dexmedetomidine to prevent the
incidence of EA that was identified in the present study.
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